Isabelle Dufresne
Plus aucun poste en cours
Historique de carrière de Isabelle Dufresne
Anciens postes connus de Isabelle Dufresne
Sociétés | Poste | Début | Fin |
---|---|---|---|
Gestion Fonds InnovExport Commandité inc
Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Private Equity Investor | 01/07/2019 | 01/03/2022 |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Directeur/Membre du Conseil | 09/07/2009 | 09/09/2013 |
Chlorion Pharma, Inc.
Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Directeur/Membre du Conseil | - | - |
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Directeur de la Recherche - Actions | - | - |
Analyste en capital-investissement | - | 25/06/2009 | |
Private Equity Investor | - | - |
Formation de Isabelle Dufresne
Université Laval | Graduate Degree |
University of Quebec | Undergraduate Degree |
Statistiques
Internationale
Canada | 7 |
Opérationnelle
Private Equity Investor | 2 |
Director/Board Member | 2 |
Director of Research - Equity | 1 |
Sectorielle
Finance | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Finance |
Chlorion Pharma, Inc.
Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Commercial Services |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Gestion Fonds InnovExport Commandité inc
Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Finance |
- Bourse
- Insiders
- Isabelle Dufresne
- Expérience